Bristol-Myers, Otsuka schizophrenia study shows positive results

By Elaine Rigoli

Tampa, Fla., May 25 - The Bristol-Myers Squibb Co. and Otsuka Pharmaceutical Co., Ltd. said Thursday that atypical antipsychotic medicine aripiprazole demonstrated significantly greater improvement on the Investigator's Assessment Questionnaire (IAQ) versus standard-of-care in a six-month, randomized, open-label, multicenter trial of more than 500 adults living with schizophrenia conducted in Europe.

The IAQ is a validated instrument that is a combined measure of efficacy, safety and tolerability, and is comprised of 10 items, according to a news release.

Standard-of-care included treatment with one of the following atypical antipsychotics: olanzapine, quetiapine or risperidone, the release said.

Bristol Myers is a global pharmaceutical company based in New York.

Otsuka is a pharmaceutical company based in Tokyo.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.